Platinum
- Generic Name
- Platinum
- Drug Type
- Small Molecule
- Chemical Formula
- Pt
- CAS Number
- 7440-06-4
- Unique Ingredient Identifier
- 49DFR088MY
- Background
Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.
Gut Microbiota Reconstruction for NSCLC Immunotherapy
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Procedure: Capsulized Fecal Microbiota TransplantDrug: Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05008861
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
- Conditions
- Chemotherapy EffectEsophagus CancerEsophagogastric Junction CancerChemoradiationTargeted TherapyImmunotherapy
- Interventions
- Radiation: RadiotherapyDrug: Immunotherapy
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 2000
- Registration Number
- NCT04821778
- Locations
- 🇨🇳
Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang, Henan, China
🇨🇳Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
Neoadjuvant Treatment Modalities in Esophageal Cancer
- Conditions
- Esophagogastric Juction CancerSurgeryImmunotherapyEsophageal CancerChemotherapy EffectTargeted TherapyChemoradiation
- Interventions
- Radiation: RadiotherpayProcedure: SurgeryDrug: Immunotherapy
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2023-11-24
- Target Recruit Count
- 2000
- Registration Number
- NCT04821843
- Locations
- 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China
Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Zhongshan Hospital Xiamen University
- Target Recruit Count
- 58
- Registration Number
- NCT04590625
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian, China
Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial
- Conditions
- Hypopharyngeal Cancer
- Interventions
- Radiation: Intensity Modulated Radiation Therapy
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 160
- Registration Number
- NCT04502641
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04453930
- Locations
- 🇨🇳
Beijing Union Medical College Hospital, Beijing, China
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Neoplasms, Head and Neck
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 117
- Registration Number
- NCT04428333
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
- Conditions
- Solid Neoplasms
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 374
- Registration Number
- NCT04420884
- Locations
- 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center, Orange, California, United States
Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 168
- Registration Number
- NCT04365023
- Locations
- 🇫🇷
Gastroenterology and digestive oncology unit - Cochin hospital, Paris, France
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Mark Vincent
- Target Recruit Count
- 200
- Registration Number
- NCT04335292
- Locations
- 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦Lions Gate Hospital, Vancouver, British Columbia, Canada
🇨🇦William Osler Health System, Brampton, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.